Research programme: microRNA therapeutics - AstraZeneca/Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - AstraZeneca/Regulus Therapeutics

Alternative Names: anti-microRNA-103/107; anti-microRNA-19; anti-microRNA-33a; anti-microRNA-33b; anti-miR-103/107; anti-miR-19; anti-miR-33a; anti-miR-33b; microRNA-103/107 therapeutics; microRNA-19 therapeutics; microRNA-33 therapeutics

Latest Information Update: 26 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MicroRNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Cancer; Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 24 Sep 2014 Preclinical development is ongoing in the US
  • 28 Oct 2013 Preclinical development is ongoing in US
  • 14 Aug 2012 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top